# The article discusses Wegovy, a new prescription weight loss drug, approved by the FDA for chronic weight management. # Wegovy is a higher-dose version of the diabetes drug semaglutide and is designed for people with a body mass index of 27 or higher. # Clinical trials have shown significant weight loss results in participants using Wegovy, with an average weight loss of 15-17%. # The drug works by reducing appetite and calorie intake while increasing feelings of fullness. ## The recent FDA approval of Wegovy has sparked interest in the weight loss community as a potential solution for chronic weight management. This higher-dose version of semaglutide has shown promising results in clinical trials, with participants experiencing an average weight loss of 15-17%. By targeting appetite control and increasing feelings of fullness, Wegovy offers a new option for individuals with a BMI of 27 or higher looking to achieve their weight loss goals. For those interested in exploring Wegovy as a weight loss option, it is essential to consult with a healthcare provider to determine if this medication is right for you. If you are considering incorporating Wegovy into your weight loss journey, Mindful Evolution offers telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia. Contact us today through our website at https://yourmindfulevolution.com or call/text us at 954-639-9960 to learn more about how we can support you in achieving your weight loss goals. Weight Loss Disclaimer: Individual results may vary. It is important to consult with a healthcare provider before starting any weight loss program or medication.